Literature DB >> 33704002

Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers.

Javier Martínez-Sanz1, Daniel Jiménez1, Laura Martínez-Campelo2, Raquel Cruz2, Pilar Vizcarra1, Matilde Sánchez-Conde1, Raquel Ron1, Mario Rodríguez3, Sabina Herrera1, Santiago Moreno1, María Rosa López-Huertas4, Sergio Serrano-Villar1.   

Abstract

We aim to evaluate the role of single-nucleotide polymorphisms of the angiotensin-converting enzyme 2 in susceptibility to SARS-CoV-2 infection. We included 28 uninfected but highly exposed healthcare workers and 39 hospitalized patients with COVID-19. Thirty-five SNPs were rationally selected. Two variants were associated with increased risk of being susceptible to SARS-CoV-2: the minor A allele in the rs2106806 variant (OR 3.75 [95% CI 1.23-11.43]) and the minor T allele in the rs6629110 variant (OR 3.39 [95% CI 1.09-10.56]). Evaluating the role of genetic variants in susceptibility to SARS-CoV-2 infection could help identify more vulnerable individuals and suggest potential drug targets for COVID-19 patients.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; genetic variants; single-nucleotide polymorphism; susceptibility

Mesh:

Substances:

Year:  2021        PMID: 33704002      PMCID: PMC7993370          DOI: 10.1080/22221751.2021.1902755

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


Background

Considering the great expansion of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the presence of highly exposed people who have not yet acquired the infection is striking. Previous studies suggest that genetic factors along with other risk factors can determine an individual’s susceptibility to respiratory tract infections; therefore they may contribute to the very high transmissibility of SARS-CoV-2, as well as to the susceptibility of each individual to infection [1]. However, these factors are largely unknown. The development of new preventive strategies for COVID-19 would be greatly facilitated by the identification of host genetic pathways and DNA polymorphisms that modulate the risk of infection [2]. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor for entry into the host cells [3]. It has been hypothesized that the ACE2 gene constitutes a genetic risk factor for SARS-CoV-2 infection [4]. In this regard, variations in the expression of ACE2 may play a significant role in determining an individual’s susceptibility to COVID-19 [1]. Moreover, several single-nucleotide polymorphisms (SNPs) of the ACE2 gene previously reported to be associated with other disorders, such as hypertension and other cardiovascular diseases, are thought to influence susceptibility to SARS-CoV-2 infection [5,6]. This phenomenon has been observed in other infections, one example being the genetic variants of the dipeptidyl peptidase-4 receptor in the case of MERS-CoV [7]. Our objective is to evaluate the role of ACE2 SNPs in the susceptibility to SARS-CoV-2 infection in a sample of highly exposed healthcare workers and patients with COVID19.

Methods

Study design and data sources

We classified participants as being susceptible or non-susceptible to SARS-CoV-2 infection. Susceptible individuals were hospitalized patients with confirmed SARS-CoV-2 infection by PCR in nasopharyngeal swabs, sputum, or lower respiratory tract secretions, within the first 7 days from the onset of symptoms. Non-susceptible participants were healthy healthcare workers who had been on duty for at least three months in COVID19 wards or intensive care units and had had at least three high-risk exposures to SARS-CoV-2 [8], without having experienced symptoms suggestive of SARS-CoV-2 infection, persistently negative PCR SARS-CoV-2 testing, and absence of SARS-CoV-2 IgM and IgG in plasma by indirect chemiluminescence immunoassay (Vircell, Granada, Spain). The most frequent type of exposures were largely unprotected exposure to aerosol-generating procedures or patient secretions, and close contact without face masks with other confirmed cases of COVID-19. We excluded subjects unable to provide informed consent or witnessed oral consent with the written consent by a representative. The study was carried out at the Ramón y Cajal University Hospital in Madrid (Spain) and was approved by the local Research Ethics Committee (ceic.hrc@salud.madrid.org, approval number 095/20).

Endpoint

The primary endpoint was the association between the ACE2 SNPs analyzed and the susceptibility to SARS-CoV-2 infection.

Genotyping of SNPs in ACE-2 gene

SNPs in ACE-2 were identified based on existing literature and human genome sequence databases. A search using the dbSNP database of NCBI yielded more than 17,000 SNPs for ACE2 gene. In order to reduce this vast number of SNPs, we performed a literature search in Pubmed database in May 2020, including the terms “ACE2, SNP” or “ACE2, polymorphism” and achieved 206 and 107 results, respectively. Then articles including information related to “COVID-19”, “SARS-CoV-2”, “mortality” and “cardiovascular disease”, “diabetes mellitus”, “obesity”, and “hypertension” were further assessed. Thirty-five SNPs were identified and rationally selected [9] (Supplemental Table 1). Total DNA was extracted from peripheral blood using QIAamp DNA Mini Kit (Qiagen), quantified using a NanoDrop-1000 (ThermoFisher, Waltham, MA), and diluted to 20 ng/μL concentration. Genotyping of the selected SNP of ACE-2 was performed using Sequenom’s MassARRAY platform (San Diego, CA, USA) and the iPLEX® Gold assay design system at the Spanish National Genotyping Center (CeGen; http://www.cegen.org/). Samples Na1086, Na11994 and Na11995 from Coriell Institute (www.coriell.org) were used as positive controls. The primers used in this study are summarized in Supplemental Table 2.

Statistical analysis

A quality control procedure was performed on each of the SNPs: genotype call rate and minor allele frequency were calculated and a visual inspection of the clusterplots was carried out. For each SNP, a logistic regression analysis was performed to assess the genetic association with susceptibility. SNPs were coded under a dominant genetic model, in which both heterozygous and rare allele homozygous were combined and compared without correction for multiple comparisons with the genotype homozygous for the most frequent allele. Gender was included in the regression model as a covariate. Analysis was performed using the SNPassoc library for R software and Stata v16.0 (StataCorp LP, College Station, TX).

Results

Study population

We included 67 participants, 39 susceptible and 28 non-susceptible individuals. The sample of susceptible subjects was representative of a medium-aged population (median age 58 [IQR 44–84] years) with a slightly higher representation of women (56%). Of them, 59% had a mild infection and 41% had COVID19 who required hospitalization. Non-susceptible healthcare workers had a median age of 43 (IQR 36–51) years and 78% were women.

SNPs in ACE2 and SARS-CoV-2 susceptibility

Of the total 35 SNPs analyzed (Supplemental Table 1), two showed an association with SARS-CoV-2 susceptibility. The minor A allele in the rs2106806 variant (AA or GA vs. GG genotype) was associated with an increased risk of being susceptible to SARS-CoV-2 infection (OR 3.75 [95% CI 1.23–11.43], p = 0.016). In the same way, the minor T allele in the rs6629110 variant (TT or TC vs. CC genotype) was associated with an increased infection susceptibility (OR 3.39 [95% CI 1.09–10.56], p = 0.029) (Table 1).
Table 1.

SNPs from ACE2 gene showing an association with SARS-CoV-2 susceptibility.

SNPGenotypeSusceptible, n (%)OR (95% CI)p-value
NoYes
rs2106806GG17 (63)15 (38.5)Ref.Ref.
GA + AA10 (37)24 (61.5)3.75 (1.23–11.43)0.0156
rs6629110CC15 (55.6)14 (35.9)Ref.Ref.
CT + TT12 (44.4)25 (64.1)3.39 (1.09–10.56)0.0289

ACE2, angiotensin-converting enzyme 2; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

SNPs from ACE2 gene showing an association with SARS-CoV-2 susceptibility. ACE2, angiotensin-converting enzyme 2; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

Discussion

In this observational work, we aimed to identify SNPs in the ACE2 gene that could confer increased susceptibility to SARS-CoV-2 infection. Two variants were associated with a 3- to a 4-fold greater risk of COVID19: rs6629110 and rs2106806. Because ACE2 is the target molecule of SARS-CoV-2 for cell entry, higher levels of ACE2 expression are expected to lead to higher levels of SARS-CoV-2 viremia. The Genotype-Tissue Expression (GTEx) database revealed that SNP rs6629110 was associated with greater expression of ACE2 [5], although researchers were not able to confirm the link between variants in the ACE2 gene and COVID-19 [10]. The SNP rs2106806 was among those included in a recent study aimed at describing a transcription regulatory network within the ACE2 locus in the context of SARS-CoV-2 infection, but no correlation was found [11]. Here, we show that the minor A allele within rs2106806 increases the risk of critical COVID-19. The allele frequency of the ACE2 SNP rs6629110 is much higher in East Asian than in European populations [5,10] but its importance during SARS-CoV-2 infection remains unknown. This variant has been associated with high expression of ACE2 in tissues such as the tibial artery [10] but, to our knowledge, an association with increased expression of ACE2 in lung tissue has not been described so far and there is no association between the variant and expression of ACE2 in nasal epithelium. Hence, this is the first report linking the rs6629110 variant with COVID19 susceptibility. However, it requires external validation in other studies. Because the mechanisms protecting low-susceptible individuals to acquire SARS-CoV-2 remain poorly understood, the main strength of our study is a novelty. We exploited a striking phenomenon, i.e. subjects without evidence of having been infected with SARS-CoV-2 despite repeated high-risk exposures to explore gene variants associated with disease susceptibility. Given the multifactorial nature of high-risk exposures, the extent of exposure to SARS-CoV-2 cannot be measured today in clinical studies, which is a limitation of our study. Because of the definition we used to classify non-susceptible individuals, we think, however, that it is very likely that this group had multiple high-risk exposures. The main limitation is the rather low number of individuals assessed, which precluded us to use a genome-wide association approach. In contrast to GWA studies, which generate thousands of untargeted variables that demand a meticulous correction for false discovery rate, we rationally selected the SNPs to be analyzed. Issues such as exposure imply that studies of genetic susceptibility to infectious diseases will have modest effect sizes and, therefore, that statistical power will be at a premium [12]. Then the greater inherent power of a rational selection of candidate SNPs may make it preferable over GWA. Indeed, because we rationally selected the SNPs in the ACE2 to be assessed based on the background literature, we did not use Bonferroni corrections to adjust for multiple comparisons, as has been recommended for targeted analyses [13]. Admittedly, the fact that the associations would not remain statistically significant after adjustment by false discovery rate demands caution when interpreting the results. The study should be considered as hypothesis-generating and the findings must be validated in larger studies. In summary, we describe two candidate variants in the ACE2 gene that were predictive of a greater risk of SARS-CoV-2 infection. Evaluating the role of genetic variants in susceptibility to SARS-CoV-2 infection could help identify more vulnerable individuals and suggest potential drug targets for COVID-19 patients. Click here for additional data file.
  11 in total

1.  Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease?

Authors:  W Amos; E Driscoll; J I Hoffman
Journal:  Proc Biol Sci       Date:  2010-10-06       Impact factor: 5.349

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

Review 3.  The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19.

Authors:  Mira Bosso; Thangavel Alphonse Thanaraj; Mohamed Abu-Farha; Muath Alanbaei; Jehad Abubaker; Fahd Al-Mulla
Journal:  Mol Ther Methods Clin Dev       Date:  2020-06-25       Impact factor: 6.698

4.  ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population.

Authors:  Elisa Benetti; Rossella Tita; Ottavia Spiga; Andrea Ciolfi; Giovanni Birolo; Alessandro Bruselles; Gabriella Doddato; Annarita Giliberti; Caterina Marconi; Francesco Musacchia; Tommaso Pippucci; Annalaura Torella; Alfonso Trezza; Floriana Valentino; Margherita Baldassarri; Alfredo Brusco; Rosanna Asselta; Mirella Bruttini; Simone Furini; Marco Seri; Vincenzo Nigro; Giuseppe Matullo; Marco Tartaglia; Francesca Mari; Alessandra Renieri; Anna Maria Pinto
Journal:  Eur J Hum Genet       Date:  2020-07-17       Impact factor: 4.246

5.  New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.

Authors:  Yuan Hou; Junfei Zhao; William Martin; Asha Kallianpur; Mina K Chung; Lara Jehi; Nima Sharifi; Serpil Erzurum; Charis Eng; Feixiong Cheng
Journal:  BMC Med       Date:  2020-07-15       Impact factor: 8.775

6.  Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.

Authors:  Yanan Cao; Lin Li; Zhimin Feng; Shengqing Wan; Peide Huang; Xiaohui Sun; Fang Wen; Xuanlin Huang; Guang Ning; Weiqing Wang
Journal:  Cell Discov       Date:  2020-02-24       Impact factor: 10.849

Review 7.  Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19.

Authors:  Sarita Choudhary; Karli Sreenivasulu; Prasenjit Mitra; Sanjeev Misra; Praveen Sharma
Journal:  Ann Lab Med       Date:  2021-03-01       Impact factor: 3.464

8.  Covid-19: risk factors for severe disease and death.

Authors:  Rachel E Jordan; Peymane Adab; K K Cheng
Journal:  BMJ       Date:  2020-03-26

Review 9.  ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.

Authors:  Christian A Devaux; Jean-Marc Rolain; Didier Raoult
Journal:  J Microbiol Immunol Infect       Date:  2020-05-06       Impact factor: 4.399

10.  Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus.

Authors:  Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Alexander Prokscha; Hassan Y Naim; Marcel A Müller; Christian Drosten; Stefan Pöhlmann; Markus Hoffmann
Journal:  Emerg Microbes Infect       Date:  2020-01-21       Impact factor: 7.163

View more
  8 in total

1.  Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis.

Authors:  Cristine Dieter; Letícia de Almeida Brondani; Cristiane Bauermann Leitão; Fernando Gerchman; Natália Emerim Lemos; Daisy Crispim
Journal:  PLoS One       Date:  2022-07-06       Impact factor: 3.752

2.  Host polymorphisms and COVID-19 infection.

Authors:  Joris R Delanghe; Marijn M Speeckaert
Journal:  Adv Clin Chem       Date:  2021-08-23       Impact factor: 5.394

Review 3.  Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children.

Authors:  Grant S Schulert; Sydney A Blum; Randy Q Cron
Journal:  Curr Opin Pediatr       Date:  2021-12-01       Impact factor: 2.856

4.  Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.

Authors:  Jingwei Li; Yali Wang; Yong Liu; Ziqu Zhang; Yuyun Zhai; Yan Dai; Zijian Wu; Xiang Nie; Lunfei Du
Journal:  Eur J Med Res       Date:  2022-02-22       Impact factor: 2.175

Review 5.  The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic.

Authors:  Maria Karoliny da Silva Torres; Carlos David Araújo Bichara; Maria de Nazaré do Socorro de Almeida; Mariana Cayres Vallinoto; Maria Alice Freitas Queiroz; Izaura Maria Vieira Cayres Vallinoto; Eduardo José Melo Dos Santos; Carlos Alberto Marques de Carvalho; Antonio Carlos R Vallinoto
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

6.  ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19.

Authors:  María Del Carmen Maza; María Úbeda; Pilar Delgado; Lydia Horndler; Miguel A Llamas; Hisse M van Santen; Balbino Alarcón; David Abia; Laura García-Bermejo; Sergio Serrano-Villar; Ugo Bastolla; Manuel Fresno
Journal:  Front Immunol       Date:  2022-03-23       Impact factor: 7.561

Review 7.  Role of genetic variants and host polymorphisms on COVID-19: From viral entrance mechanisms to immunological reactions.

Authors:  Abolfazl Adli; Mandana Rahimi; Reza Khodaie; Niloofar Hashemzaei; Sayed M Hosseini
Journal:  J Med Virol       Date:  2022-02-08       Impact factor: 20.693

Review 8.  Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19.

Authors:  Rafael Silva Lima; Luiz Paulo Carvalho Rocha; Paula Rocha Moreira
Journal:  Cell Biochem Funct       Date:  2021-06-01       Impact factor: 3.963

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.